Atypical antipsychotics linked to cardiac death
Treatment with atypical antipsychotics like Lilly's Zyprexa (olanzapine), AstraZeneca's Seroquel (quetiapine) and risperidone (Johnson & Johnson's Risperdal and generics) resulted in sudden cardiac death at twice the rate as that seen in patients who did not take the drugs in a retrospective cohort study appearing in the New England Journal of Medicine Jan. 15. Atypical antipsychotics, used to treat schizophrenia and bipolar disorder, have long been considered safer alternatives to older typical antipsychotic medicines. The retrospective analysis, however, found the incidence rate ratios among users of atypical antipsychotics (1.59 for low doses to 2.46 for higher doses) to be similar to that seen among users of typical antipsychotics. The research, funded by HHS' Agency for Healthcare Research and Quality, could have implications for how the drugs are used for depression or other off-label uses
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.